➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Mallinckrodt
Merck
Moodys
AstraZeneca

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

LANOXIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Lanoxin, and when can generic versions of Lanoxin launch?

Lanoxin is a drug marketed by Covis Pharma Bv and Concordia and is included in two NDAs.

The generic ingredient in LANOXIN is digoxin. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the digoxin profile page.

US ANDA Litigation and Generic Entry Outlook for Lanoxin

A generic version of LANOXIN was approved as digoxin by MYLAN PHARMS INC on December 23rd, 1999.

  Start Trial

Drug patent expirations by year for LANOXIN
Drug Prices for LANOXIN

See drug prices for LANOXIN

Drug Sales Revenue Trends for LANOXIN

See drug sales revenues for LANOXIN

Recent Clinical Trials for LANOXIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 1
Janssen Research & Development, LLCPhase 1
National Cancer Institute (NCI)Phase 2

See all LANOXIN clinical trials

Pharmacology for LANOXIN

US Patents and Regulatory Information for LANOXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv LANOXIN digoxin INJECTABLE;INJECTION 009330-002 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-006 Sep 30, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-003 Sep 30, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Covis Pharma Bv LANOXIN PEDIATRIC digoxin INJECTABLE;INJECTION 009330-004 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-001 Sep 30, 1997 RX Yes No   Start Trial   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-002 Sep 30, 1997 AB RX Yes No   Start Trial   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-005 Sep 30, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.